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A B S T R A C T   
Although Nile tilapia (Oreochromis niloticus) is a well-established aquaculture species globally, there are a limited number of commercial vaccines available or are 
used for this species. The majority of diseases affecting farmed tilapia are bacterial, with antibiotics frequently used to treat fish. The current study was performed to 
optimise the use of mucosal vaccines for tilapia by adapting an existing bacterin vaccine against Francisella noatunensis subsp. orientalis (Fno) as a proof of concept. 
This vaccine has previously provided excellent protection by injection, however, the preference for tilapia farmers would be to vaccinate fish by immersion or orally, 
due to the lower cost and ease of application. These vaccination routes, however, are often less efficacious probably due to the lack of adjuvants in immersion and 
oral vaccines. The aims of this study, therefore, were to optimise the formulation and dose of the Fno vaccine with mucosal adjuvants for oral and immersion delivery. 
Tilapia fry (av. 6 g) were given three concentrations (high, medium, low; i.e. 1×109, 1×108 and 1×107 CFU mL-1) of antigen combined with the oral adjuvant by oral 
gavage, to optimise the dose needed to induce an immune response to Fno, and the immune response obtained compared with fish vaccinated by immersion (with and 
without an immersion adjuvant). Fry were boosted by the same route at 420 degree days (DD), and samples (serum, mucus ) taken at 840 DD for specific antibody 
responses measured by ELISA and western blotting. Specific IgM titres were significantly elevated in serum and mucus of fish given the high dose adjuvanted vaccine 
by gavage. In addition, by western blotting with serum, a significant immunogenic reaction was evident between 20 and 37 kDa in the fish given the high dose oral 
vaccine by gavage. As protection against Fno provided by the injection vaccine was correlated with specific antibody responses these findings suggest the oral vaccine 
also has potential to provide protection. Further studies are needed to optimise delivery of the vaccine via feed.   
A significant proportion of the diseases affecting farmed Nile tilapia, 
Oreochromics niloticus, are bacterial, with antibiotics frequently used to 
treat fish. Of the few vaccines available commercially for tilapia, most 
tend to be administered by injection. Due to the lower cost and ease of 
their application, mucosal vaccines (immersion/oral) are an ideal route 
of vaccine delivery for this species. There is, however, a need to develop 
and optimise mucosal adjuvants to enhance the immunogenicity and 
length of protection elicited by mucosal vaccines [1–3]. This study was 
performed to give preliminary data on a novel oral adjuvant (Essai 
GR01, Seppic Courbevoie, France) by adapting a protective injectable 
vaccine [4] against a common bacterial pathogen of tilapia, Francisella 
noatunensis subsp. orientalis (Fno). 
Nile tilapia fry were maintained in a recirculation system within the 
research aquarium facility of Benchmark R&D Ltd., in Thailand. An 
isolate of Fno obtained from a francisellosis outbreak in the UK was used 
to formulate the vaccine as previously described [4]. Tilapia (5.97 ±
0.19 g) were given an Fno antigen/Seppic oral adjuvant (30% anti-
gen:70% adjuvant) by oral gavage. Three concentrations of Fno antigen 
were tested in the vaccine (high, medium, low, i.e., 1 × 109, 1 × 108 and 
1 × 107 CFU mL− 1, respectively) and the antibody response compared 
with fish vaccinated by immersion (1 × 108 CFU mL− 1 inactivated Fno 
with and without an immersion adjuvant; IMS 1312 VG PR, Seppic). 
Groups of tilapia (n = 30/dose) were sedated using benzocaine (100 mg 
mL− 1, 10%, Sigma-Aldrich Company Ltd., UK) and a 0.05 mL dose of 
oral vaccine applied into the stomach of the fish using a 20 gauge im-
plantation tubing attached to a 2 mL syringe. The immersion adjuvant 
(IMS 1312 VG PR) was mixed with the formalin-inactivated vaccine 
concentrated to 2 × 109 CFU mL-1 (1:1) before diluting with tank water 
to give a final adjuvant concentration of 5%. Non-adjuvanted vaccine 
was prepared in same way, using sterile PBS in place of adjuvant. For 
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immersion vaccination, two groups of fry (n = 30) were removed from 
the holding tank with a net and placed in the container of vaccine-
±adjuvant for 30 s at 28 ◦C ±1. Fry were maintained at 28 ◦C ±1 
throughout the vaccination period. Tissue samples were taken at day 1 
and 2 post-vaccination (pv) for antigen uptake by immunohistochem-
istry. Fry were booster vaccinated by the respective methods (oral or 
immersion) as described above at 420 degree DD. Fish were sampled (n 
= 6) for skin mucus and blood at 0 and 30-days post-vaccination (dpv) 
(840 DD). An indirect ELISA was used to measure the specific antibody 
response in serum and mucus as previously described [4]; mucus sam-
ples were applied to the ELISA plate at a 1/5 dilution. Western blotting 
was also performed as described in Ref. [4]. Tilapia given the adju-
vanted oral vaccine by gavage containing the highest dose of antigen (1 
× 109, CFU mL− 1), had significantly higher levels of anti-Fno IgM in both 
serum and mucus than pre-vaccinated control fish at 0 dpv, fish vacci-
nated orally with the medium or low dose of antigen, and the immersion 
vaccinated fish (Table 1). 
Tissue samples (0, 1, 2 dpv; n = 3) were analysed by immunohisto-
chemistry (IHC) for uptake of the vaccine antigen (Fno) according to 
Ref. [5]. The presence of vaccine antigen was observed in immersion 
vaccinated fish at 1 dpv in gills, skin, gut and spleen and in orally 
vaccinated fish it was observed at 2 days post-oral vaccination in the gut 
and spleen, with the antigen in the spleen only seen in fish given the high 
dose of oral vaccine (data not shown). 
By western blotting with serum, a significant immunogenic reaction 
was evident between 20 and 37 kDa in the fish given the high dose oral 
vaccine by gavage (Fig. 1, lane 3). This region was also strongly stained 
with serum from fish given intraperitoneal (i.p.) vaccination with an oil 
adjuvanted vaccine against Fno (obtained from the study of [4]) and is 
associated with the pathogenicity island of Fno [6] (Fig. 1, Lane 4). 
Previously, protection observed with the injectable Fno vaccine (relative 
percentage survival of 82%) was linked to specific serum antibodies [4]. 
Further studies are needed to optimise delivery of the oral vaccine by 
feeding and to the determine efficacy of the adjuvanted oral vaccine 
presented here. 
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a Denotes significant differences between groups at p < 0.0001 or at * p <
0.009, (n = 6), days post vaccination (dpv). 
Fig. 1. Western blot of Francisella noatunensis subsp. orientalis (Fno) incubated 
with serum from Nile tilapia, Oreochromis niloticus. Lanes: (1) control; (2) im-
mersion (+adjuvant) vaccinated; (3) oral gavage vaccinated (high dose); (4) 
positive control (intraperitoneally vaccinated). Brace indicates the strongly 
immunogenic area 20–37 kDa associated with the pathogenicity island of Fno. 
kDa: Kilo Dalton molecular weight. 
R. Hoare et al.                                                                                                                                                                                                                                   
Fish and Shellfish Immunology 113 (2021) 86–88
88
tilapia, Oreochromis niloticus (L), against multiple isolates of Francisella noatunensis 
subsp. orientalis from diverse geographical regions, Fish Shellfish Immunol. 89 
(2019), https://doi.org/10.1016/j.fsi.2019.03.071. 
[5] W.A.S. Djainal, K. Shahin, M. Metselaar, A. Adams, A.P. Desbois, Larva of greater 
wax moth Galleria mellonella is a suitable alternative host for the fish pathogen 
Francisella noatunensis subsp. orientalis, BMC Microbiol. 20 (2020) 1–14, https://doi. 
org/10.1186/s12866-020-1695-0. 
[6] J. Lewis, E. Soto, Gene expression of putative type VI secretion system (T6SS) genes 
in the emergent fish pathogen Francisella noatunensis subsp. orientalis in different 
physiochemical conditions, BMC Microbiol. 19 (2019) 1, https://doi.org/10.1186/ 
s12866-019-1389-7. 
R. Hoare et al.                                                                                                                                                                                                                                   
